Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9045)
All Articles published online
|
Publishing Process of This Article
|
Feb 6, 2017 (publication date) through Apr 18, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chang WCL, Masih S, Thadi A, Patwa V, Joshi A, Cooper HS, Palejwala VA, Clapper ML, Shailubhai K. Plecanatide-mediated activation of guanylate cyclase-C suppresses inflammation-induced colorectal carcinogenesis in Apc+/Min-FCCC mice. World J Gastrointest Pharmacol Ther 2017; 8(1): 47-59 [PMID: 28217374 DOI: 10.4292/wjgpt.v8.i1.47] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v8/i1/47.htm |
| Number | Citing Articles |
| 1 |
John C Flickinger, Jeffrey A Rappaport, Joshua R Barton, Trevor R Baybutt, Amanda M Pattison, Adam E Snook, Scott A Waldman. Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies. Biomarkers in Medicine 2021; 15(3): 201 doi: 10.2217/bmm-2020-0359
|
| 2 |
Erik S. Blomain, Jeffrey A. Rappaport, Amanda M. Pattison, Babar Bashir, Ellen Caparosa, Jonathan Stem, Adam E. Snook, Scott A. Waldman. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis. Cancer Biology & Therapy 2020; 21(5): 441 doi: 10.1080/15384047.2020.1721262
|
| 3 |
Hari Prasad, John Kandam Kulathu Mathew, Sandhya S. Visweswariah. Receptor Guanylyl Cyclase C and Cyclic GMP in Health and Disease: Perspectives and Therapeutic Opportunities. Frontiers in Endocrinology 2022; 13 doi: 10.3389/fendo.2022.911459
|
| 4 |
N.S. Yarla, H. Gali, G. Pathuri, S. Smriti, M. Farooqui, J. Panneerselvam, G. Kumar, V. Madka, C.V. Rao. Targeting the paracrine hormone-dependent guanylate cyclase/cGMP/phosphodiesterases signaling pathway for colorectal cancer prevention. Seminars in Cancer Biology 2019; 56: 168 doi: 10.1016/j.semcancer.2018.08.011
|
| 5 |
Avelina Lee, Iryna Lebedyeva, Wenbo Zhi, Vani Senthil, Herjot Cheema, Michael W. Brands, Weston Bush, Nevin A. Lambert, Madeline Snipes, Darren D. Browning. A Non-Systemic Phosphodiesterase-5 Inhibitor Suppresses Colon Proliferation in Mice. International Journal of Molecular Sciences 2023; 24(11): 9397 doi: 10.3390/ijms24119397
|
| 6 |
Ariana A. Entezari, Adam E. Snook, Scott A. Waldman. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential. Expert Opinion on Therapeutic Targets 2021; 25(5): 335 doi: 10.1080/14728222.2021.1937124
|
| 7 |
Yali Hou, Alexis Wren, Namratha Mylarapu, Kaylin Browning, Bianca N. Islam, Rui Wang, Kenneth J. Vega, Darren D. Browning. Inhibition of Colon Cancer Cell Growth by Phosphodiesterase Inhibitors Is Independent of cGMP Signaling. Journal of Pharmacology and Experimental Therapeutics 2022; 381(1): 42 doi: 10.1124/jpet.121.001075
|
| 8 |
Shuai Chen, Jianghong Cheng, Yanhong Zhong, Ruimin Liu, Zhongxian Lu, Xianyang Luo. Liver-specific overexpression of Gab2 accelerates hepatocellular carcinoma progression by activating immunosuppression of myeloid-derived suppressor cells. Oncogene 2022; 41(24): 3316 doi: 10.1038/s41388-022-02298-7
|
| 9 |
Chenxi He, Yilong Zhou, Feng Liu, Haipeng Liu, Hao Tan, Shouguang Jin, Weihui Wu, Baoxue Ge, Beth McCormick. Bacterial Nucleotidyl Cyclase Inhibits the Host Innate Immune Response by Suppressing TAK1 Activation. Infection and Immunity 2017; 85(9) doi: 10.1128/IAI.00239-17
|
| 10 |
Sarah K. Sharman, Bianca N. Islam, Yali Hou, Nagendra Singh, Franklin G. Berger, Subbaramiah Sridhar, Wonsuk Yoo, Darren D. Browning. Cyclic-GMP–Elevating Agents Suppress Polyposis in ApcMin Mice by Targeting the Preneoplastic Epithelium. Cancer Prevention Research 2018; 11(2): 81 doi: 10.1158/1940-6207.CAPR-17-0267
|
| 11 |
Adi Caspi, Ariana A Entezari, Madison Crutcher, Adam E Snook, Scott A Waldman. Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer. Personalized Medicine 2022; 19(5): 457 doi: 10.2217/pme-2022-0026
|
| 12 |
Vishwas Mishra, Kritica Sharma, Avipsa Bose, Pierre Maisonneuve, Sandhya S. Visweswariah. The evolutionary divergence of receptor guanylyl cyclase C has implications for preclinical models for receptor-directed therapeutics. Journal of Biological Chemistry 2024; 300(1): 105505 doi: 10.1016/j.jbc.2023.105505
|
| 13 |
Stuart M. Brierley, Luke Grundy, Joel Castro, Andrea M. Harrington, Gerhard Hannig, Michael Camilleri. Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain. Trends in Pharmacological Sciences 2022; 43(2): 110 doi: 10.1016/j.tips.2021.11.002
|
| 14 |
Jeffrey A. Rappaport, Scott A. Waldman. The Guanylate Cyclase C—cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. Frontiers in Oncology 2018; 8 doi: 10.3389/fonc.2018.00299
|
| 15 |
Dejan Simic, Aleksandar Spasic, Mirko Jovanovic, Predrag Maric, Radovan Milosevic, Ivan Srejovic. The Phosphodiesterase-5 Inhibitors and Prostate Cancer – What We Rely Know About It?. Serbian Journal of Experimental and Clinical Research 2019; 0(0) doi: 10.1515/sjecr-2017-0073
|
| 16 |
Jeffrey A. Rappaport, Scott A. Waldman. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer. Expert Review of Clinical Pharmacology 2020; 13(10): 1125 doi: 10.1080/17512433.2020.1826304
|
| 17 |
Illona-Marie Boulete, Anusha Thadi, Catherine Beaufrand, Viren Patwa, Apoorva Joshi, John A Foss, E Priya Eddy, Helene Eutamene, Vaseem A Palejwala, Vassilia Theodorou, Kunwar Shailubhai. Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models. World Journal of Gastroenterology 2018; 24(17): 1888-1900 doi: 10.3748/wjg.v24.i17.1888
|
| 18 |
Amanda M. Pattison, Joshua R. Barton, Ariana A. Entezari, Alicja Zalewski, Jeff A. Rappaport, Adam E. Snook, Scott A. Waldman. Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity. Cancer Biology & Therapy 2020; 21(9): 799 doi: 10.1080/15384047.2020.1779005
|
| 19 |
Gabrio Bassotti, Paolo Usai Satta, Massimo Bellini. Plecanatide for the treatment of chronic idiopathic constipation in adult patients. Expert Review of Clinical Pharmacology 2019; 12(11): 1019 doi: 10.1080/17512433.2019.1670057
|